Navigation Links
Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimer's Disease
Date:6/9/2008

each of the five primary aspects of the disease -- memory, thinking, activities of daily living, behavior and overall clinical function. Significant gains over placebo were evident after as little as 12 weeks of treatment, and were maintained after both six months and a full year of treatment. Importantly, overall benefit compared to placebo continued to increase over time, and was larger at one year than at six months. Dimebon was well-tolerated throughout the entire one-year treatment period. The majority of adverse events were mild. Dry mouth (18.0 percent Dimebon, 1.1 percent placebo) and depressed mood were the most common events. Patients treated with Dimebon experienced significantly fewer serious adverse events than those treated with placebo at one year.

About Dimebon

Dimebon is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's disease and Huntington's disease, making it a potential treatment for these and other neurodegenerative diseases. Preclinical data generated to date suggest that Dimebon operates through a novel mitochondrial mechanism of action.

Medivation is also evaluating Dimebon in an ongoing Phase 2 clinical trial in Huntington's disease.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases of the central nervous system and cancers for which there are limited treatment options. Medivation aims to revolutionize the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon(TM) in Alzheimer's disease, a Phase 2 clinical trial of Dimebon in patients with Huntington's disease, and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prost
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
2. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
3. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
4. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
5. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
6. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
7. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
8. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
9. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
10. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
11. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... BRIDGEWATER, N.J. , Sept. 16, 2014 /PRNewswire/ ... pharmaceutical company focused on developing and commercializing therapeutic ... renal and infectious diseases, announces the amendment and ... and E preferred stock and related warrants, as ... 2014 common stock and warrant financing, to remove ...
(Date:9/16/2014)... Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY ... quality and novel medicines to physicians and patients at ... Mark Baum will be a presenter at the ... New York City.  Mr. Baum will discuss the company,s ... in ophthalmology. The presentation is scheduled for 10:40 a.m. EST ...
(Date:9/16/2014)... Sept. 16, 2014  Wearable sports and activity ... less than two years, producing a massive amount ... huge opportunity exists for leveraging this data to ... ) introduced a first-of-its-kind wearable analytics platform for ... of clinical research linking activity and health risks, ...
Breaking Medicine Technology:CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3
... Inc., a pioneer in the area of digital PCR, is ... to evaluate the capabilities of digital PCR and see the ... will start on Monday, September 12 in Boston and finish ... The QuantaLife ddPCR System claims to be the world,s most ...
... SILVER SPRING, Md., Aug. 26, 2011 The FDA ... ensuring the safety of their food and medical supplies ... week,s expected hurricane-related rain, possible flooding and power outages. ... The agency also reminds consumers that it is important ...
Cached Medicine Technology:QuantaLife™ Kicks Off Droplet Digital™ PCR Road Show 2FDA Hurricane Preparedness Checklist 2FDA Hurricane Preparedness Checklist 3FDA Hurricane Preparedness Checklist 4
(Date:9/16/2014)... use among teens in the United States is on the ... the new study also found that alcohol use, binge drinking ... the ages of 12 and 17 also dropped between 2002 ... 12 and older across the United States revealed that between ... age group also dropped from 8.9 percent to 5.2 percent. ...
(Date:9/16/2014)... equally preserved in cancer patients suffering from malignant spinal ... 10 Gy of radiation therapy (RT), compared to patients ... RT each, according to research presented today at the ... , Malignant spinal cord compression (MSCC) is a ... occurs when a tumor,s secondary deposit presses on the ...
(Date:9/16/2014)... to be on the heavy side. Researchers at the ... seven in every ten obese adults underestimate how much ... much less often. Mothers of overweight or obese children ... misjudge their obese mothers, size, says lead author Tracy ... in the Journal of General Internal Medicine , ...
(Date:9/16/2014)... -- While abnormalities in the adrenergic and noradrenergic ... thought to play a role in the development ... has been no genetic evidence of this connection. ... Columbia University,s Mailman School of Public Health and ... the ADRB2 gene and childhood adversity. For individuals ...
(Date:9/16/2014)... The Pain Center of Arizona (TPC), ... has selected Analance ™, Ducen ’s BI ... TPC seeing hundreds of thousands of patients annually, the ... through “home grown” systems trying to piece together actionable ... “Our current tools were not scalable and, in ...
Breaking Medicine News(10 mins):Health News:Fewer U.S. Teens Using Illegal Drugs and Alcohol, Report Finds 2Health News:Cancer patients with malignant spinal cord compression have preserved mobility 2Health News:Cancer patients with malignant spinal cord compression have preserved mobility 3Health News:Cancer patients with malignant spinal cord compression have preserved mobility 4Health News:Poor body size judgement can lead to increased tolerance of obesity 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 2Health News:Evidence of genetic link to PTSD in soldiers exposed to childhood trauma 3Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3
... business of recruiting,university students and new graduates is ... on this talent pool to,refresh the workforce with ... changed their university recruiting methods and programs,in decades ... a leading,pharmaceutical research firm., The study analyzes ...
... need to be aware of the connection, study says ... between diabetes and depression apparently cuts both ways: Not ... a heightened risk for developing depression, individuals with depression ... research revelation suggests that both doctors and patients need ...
... Foundation,announced the winners of its annual "Healthy Communities ... 10 at its offices in Edison, N.J.,Twelve New ... year,s,calendar and each received an iPOD shuffle., ... importance,of a healthy lifestyle and promotes awareness of ...
... Million in Savings in Past 4 Years, HARRISBURG, ... saving taxpayer funds, they should support,the Department of Public ... less for prescription drugs for children and families who ... Welfare,Estelle B. Richman said today., "Every budget season ...
... the University of Pennsylvania School of Medicine found that ... cell and developmental biology leads to an increase in ... therapies for lung-tissue repair after injury or disease. The ... of print publication in Nature Genetics . , ...
... Continues to Draw Top Research Institutes,Talent, and Corporate Labs That Are Looking ... ... Future, SAN DIEGO, June 17 /Xinhua-PRNewswire/ -- Singapore,s investment ... the fastest growing bioclusters in the world. R&D spending in the,biomedical sciences ...
Cached Medicine News:Health News:Best Practices: Achieving Excellence in Staffing and Recruiting Methods 2Health News:Diabetes and Depression Go Hand-in-Hand 2Health News:Diabetes and Depression Go Hand-in-Hand 3Health News:AMERIGROUP Foundation Announces Winners of 'Healthy Communities Art Project' 2Health News:PA Secretary of Public Welfare Urges General Assembly To Support Saving $100 Million Through Smarter Pharmacy Benefit Management 2Health News:PA Secretary of Public Welfare Urges General Assembly To Support Saving $100 Million Through Smarter Pharmacy Benefit Management 3Health News:Penn researchers find key developmental pathway activates lung stem cells 2Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 2Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 3Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 4Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 5Health News:Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research 6
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: